Part 2 – How to Use LyoDots in Diagnostic Devices
In Part 1 of this two-part series we highlighted the characterization and functions of LyoDots® and now in Part 2 we uncover specific LyoDots benefits that can be incorporated in
News & Blog
Part 1 – Transforming Diagnostic Device Development with LyoDots
LyoDots® are a unique miniaturized format of lyophilized reagent that can revolutionize diagnostic device development. In this two-part series we explore how instrument and assay designers can take advantage of
Entrepreneurial Insights from Wayne Woodard, CEO of Argonaut Manufacturing Services on “Executing the Vision”
In the latest episode of Executing the Vision, Brad Hunter of Emerge Labs interviews Wayne Woodard, CEO of Argonaut Manufacturing Services, who shares his journey from college athlete to founding a
The Advantages of Lyophilizing Assay Reagents
With an ever increasing need to reduce our carbon footprint, we need to find alternative solutions to our shared challenges, and biotechnology- for all it’s good, must be included. The
Overcoming Challenges in Combination Product Manufacturing
Addressing novel modalities create the largest challenges in combination product manufacturing. Challenges in combination product manufacturing must overcome what has traditionally been two different manufacturing disciplines. At Argonaut Manufacturing Services,
Abzena and Argonaut Partner to Offer Accelerated End-to-End Drug Development Support for Biopharmaceutical Companies
Biopharma gains a seamless transition from drug discovery through drug product manufacturing San Diego, CA, June 20, 2024 – Abzena, the leading end-to-end integrated contract and development manufacturing organization (CDMO)
Five Advantages of Dual-Sourcing in Pharmaceutical Fill/Finish – Understanding the Imperative
How resilient is your manufacturing strategy in the face of potential disruptions to the pharmaceutical supply chain? As we navigate the complex landscape of aseptic drug product manufacturing, the pursuit
Strengthening Argonaut’s leadership position with investment from NewVale Capital and Telegraph Hill Partners
Argonaut Manufacturing Services Expands Aseptic Pharmaceutical Fill / Finish Capabilities with $45 Million Equity Investment from NewVale Capital and Telegraph Hill Partners Investment strengthens Argonaut’s leadership position in sterile fill
Navigating Uncharted Territories: Orphan Drug Aseptic Fill Finish, Clinical Trials, and the Impact of Advocacy
Supporting Orphan Drug Aseptic Fill Finish Rare diseases, also known as orphan diseases, are a group of diverse and often life-threatening conditions that collectively affect a small percentage of the
Expanding in Combination Product and Drug Fill/Finish – Starting 2024 Strong
Why Your Biotech Contract Manufacturer is Expanding in Combination Product and Drug-Fill/Finish in 2024 Letter to Our Colleagues, from Founder/CEO Wayne Woodard, Argonaut Manufacturing Services As 2024 gets underway, I’d